Unity Looks Ahead To Pivotal Study With Positive DME Data For UBX1325

 
• By Alaric DeArment

The company announced 24-week results from the Phase II BEHOLD trial in diabetic macular edema patients already treated with anti-VEGF therapy, showing gains in a tough population.

Unity Biotechnology announced data from the Phase II BEHOLD trial in DME • Source: Shutterstock

More from Clinical Trials

More from R&D